Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Apr
12
2022
No April Fools: Starting April 1st, Cannabis Operators Face CEQA Compliance Requirements for State Licenses Sheppard, Mullin, Richter & Hampton LLP
Apr
12
2022
Another Chocolate Class Action Lawsuit Dismissed Keller and Heckman LLP
Apr
11
2022
FDA Completes Review of GE Canola Seeds After Response to Last Year’s Inadvertent Release Keller and Heckman LLP
Apr
11
2022
PLCB Bans CBD Norris McLaughlin P.A.
Apr
11
2022
U.S. Department Of Justice Issues Guidance Concerning Legal Protections For Individuals Recovering From Opioid Use Disorder Jackson Lewis P.C.
Apr
10
2022
McDermottPlus Check-Up: April 8, 2022 McDermott Will & Emery
Apr
8
2022
ICYMI: US House Passes Recreational Marijuana Bill Strassburger McKenna Gutnick & Gefsky
Apr
8
2022
NNI Publishes Supplement to President Biden’s 2022 Budget Bergeson & Campbell, P.C.
Apr
8
2022
Prosecutors Target Fake COVID-19 Immunization and Vaccination Cards ArentFox Schiff LLP
Apr
8
2022
But I Didn’t Inhale! Employee Drug Tests in a CBD World Bradley Arant Boult Cummings LLP
Apr
7
2022
Federal Court Dismisses Disability Discrimination Suit Based on Employee’s CBD Use Jackson Lewis P.C.
Apr
7
2022
New Florida Law Allows Telemedicine Prescribing of Controlled Substances Foley & Lardner LLP
Apr
7
2022
FDA and FTC Issue Warning Letters to CBD Companies Keller and Heckman LLP
Apr
7
2022
Bill Approved by House Legalizing Marijuana Also Would Affect Immigrants Jackson Lewis P.C.
Apr
6
2022
USDA Amends Organic Origin of Livestock Requirements Keller and Heckman LLP
Apr
6
2022
Don’t Fire Me! I’m Drug Free! It Was CBD! Indiana Court Examines Termination for Use of Hemp Oil Bradley Arant Boult Cummings LLP
Apr
5
2022
Challenge to Dietary Supplement Structure/Function Claims Preempted Keller and Heckman LLP
Apr
4
2022
FDA Confirms N-acetyl-L-cysteine (NAC) is Excluded From the Dietary Supplement Definition and Leaves Open Potential Rulemaking to Allow the use of NAC in Dietary Supplements Keller and Heckman LLP
Apr
4
2022
The House Does It Again: MORE Act Ready for Senate Action Sheppard, Mullin, Richter & Hampton LLP
Apr
4
2022
SCOTUS Cert Recap: Copyright Act’s Fair Use Defense, ‘Dormant’ Commerce Clause, And Independent And Adequate State Ground Doctrine Barnes & Thornburg LLP
Apr
2
2022
Quest Diagnostics Study Finds Highest Drug Positivity Rate in Twenty Years Jackson Lewis P.C.
Apr
1
2022
Federal Judge Blocks Louisiana Labeling Law Keller and Heckman LLP
Apr
1
2022
Top 5 Insights for Cosmetic Manufacturers for 2022 Foley & Lardner LLP
Apr
1
2022
What Happens When Everyone Isn’t So Chill? Confessions of a Litigator in the Cannabis Industry Bradley Arant Boult Cummings LLP
Mar
31
2022
Supreme Court to Review California Prop 12 Keller and Heckman LLP
Mar
30
2022
Ninth Circuit Blocks New Acrylamide Warning Lawsuits Under Proposition 65 ArentFox Schiff LLP
Mar
30
2022
Movement On CMRE Act and MORE Act On Capitol Hill Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2022
FDA Requests $8.4 Billion to Further Public Health Efforts Keller and Heckman LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins